From: Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
Drug treatment | IC50 (μM) | Fold reduction of IC50 (single/combined) |
---|---|---|
Niclosamide-ivermectin | ||
 Niclosamide | 0.20 |  |
  Niclosamide + ivermectin 0.4 μM | ND | ND |
  Niclosamide + ivermectin 0.2 μM | ND | ND |
  Niclosamide + ivermectin 0.1 μM | 0.084 | 2.38 |
  Niclosamide + ivermectin 0.05 μM | 0.086 | 2.33 |
 Ivermectin | 0.20 |  |
  Ivermectin + niclosamide 0.4 μM | ND | ND |
  Ivermectin + niclosamide 0.2 μM | ND | ND |
  Ivermectin + niclosamide 0.1 μM | 0.055 | 3.64 |
  Ivermectin + niclosamide 0.05 μM | 0.083 | 2.41 |